🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes based on the I-SPY 2 Trial. #ICYMI biorxiv.org/content/10.110…

Join Exai at #ASCO24 where we will share promising new data. #EarlyDetection #MRD

Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD

Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD

We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai. lnkd.in/gwJN2c5M

Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai

Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF

💥New Publication Alert in Nature Communications 💥 Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods. Generative AI combined with unique RNA biomarkers will

We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.

Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire us: “The time is always right to do what is right.” At Exai Bio, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to earlier

#ICYMI, our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #RNA #EarlyDetection #LungCancer

Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from the American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. We are grateful for

Together we unite to fight cancer and inspire hope. #WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer

My Density Matters is hosting the 5th Annual Find out My Breast Density Day. DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer, and mammograms may not be as effective for them? We’re joining My Density Matters to

Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect early stage colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi (@aroknabadi)

💥New Publication Alert in Clinical Cancer Research💥 We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. In the independent validation set, we achieved an overall sensitivity of 89%

Congratulations to our Board Director Karen Knudsen (Karen Knudsen, MBA PhD) MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the

Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. The theme this year, “Driving Knowledge to Action: Building a Better Future” resonates with all of us at Exai Bio as we do our